請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35505
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊雅倩 | |
dc.contributor.author | Yen-Chun Lin | en |
dc.contributor.author | 林彥君 | zh_TW |
dc.date.accessioned | 2021-06-13T06:55:52Z | - |
dc.date.available | 2005-08-04 | |
dc.date.copyright | 2005-08-04 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-07-27 | |
dc.identifier.citation | 1. PA. Rota, MS. Oberste, SS. Monroe, WA. Nix, R. Campagnoli, JP. Icenogle, S. Peñaranda, B. Bankamp, K. Maher, MH. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, JL. DeRisi, Q. Chen, D. Wang, DD. Erdman, TC. Peret, C. Burns, TG. Ksiazek, PE. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Günther, AD. Osterhaus, C. Drosten, MA. Pallansch, LJ. Anderson, WJ. Bellini. (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 300(5624): 1394-1399.
2. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 based on data as of the 31 December 2003. http://www.who.int/csr/sars/country/table2004_04_21/en/ 3. PR. Hsueh, PC. Yang. (2005) Severe acute respiratory syndrome epidemic in Taiwan, 2003. J Microbiol Immunol Infect. 38(2): 82-88. 4. N. Lee, D. Hui, A. Wu, P. Chan, P. Cameron, GM. Joynt, A. Ahuja, MY. Yung, CB. Leung, KF. To, SF. Lui, CC. Szeto, S. Chung, JJ. Sung. (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 348(20): 1986-1994. 5. KW. Tsang, PL. Ho, GC. Ooi, WK. Yee, T. Wang, M. Chan-Yeung, WK. Lam, WH. Seto, LY. Yam, TM. Cheung, PC. Wong, B. Lam, MS. Ip, J. Chan, KY. Yuen, KN. Lai. (2003) A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 348(20): 1977-1985. 6. K. Stadler, V. Masignani, M. Eickmann, S. Becker, S. Abrignani, HD. Klenk, R. Rappuoli. (2003) SARS--beginning to understand a new virus. Nat Rev Microbiol. 1(3): 209-218. 7. HY. Sun, CT. Fang, JT. Wang, YC. Chen, SC. Chang. (2003) Treatment of severe acute respiratory syndrome in health-care workers. Lancet. 362(9400): 2025-2026. 8. S. Navas-Martín, SR. Weiss. (2004) Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development. J Neurovirol. 10(2): 75-85. 9. C. Drosten, S. Günther, W. Preiser, S. van der Werf, HR. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, RA. Fouchier, A. Berger, AM. Burguière, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, JC. Manuguerra, S. Müller, V. Rickerts, M. Stürmer, S. Vieth, HD. Klenk, AD. Osterhaus, H. Schmitz, HW. Doerr. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 348(20): 1967-1976. 10. JS. Peiris, ST. Lai, LL. Poon, Y. Guan, LY. Yam, W. Lim, J. Nicholls, WK. Yee, WW. Yan, MT. Cheung, VC. Cheng, KH. Chan, DN. Tsang, RW. Yung, TK. Ng, KY. Yuen, and members of the SARS study group. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 361:1319–1325. 11. RA. Fouchier, T. Kuiken, M. Schutten, G. van Amerongen, GJ. van Doornum, BG. van den Hoogen, M. Peiris, W. Lim, K. Stöhr, AD. Osterhaus. (2003) Aetiology: Koch’s postulates fulfilled for SARS virus. Nature. 423: 240 12. TG. Ksiazek, D. Erdman, CS. Goldsmith, SR. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, JA. Comer, W. Lim, PE. Rollin, SF. Dowell, AE. Ling, CD. Humphrey, WJ. Shieh, J. Guarner, CD. Paddock, P. Rota, B. Fields, J. DeRisi, JY. Yang, N. Cox, JM. Hughes, JW. LeDuc, WJ. Bellini, LJ. Anderson, and the SARS Working Group. (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 348(20): 1953-1966. 13. EJ. Snijder, PJ. Bredenbeek, JC. Dobbe, V. Thiel, J. Ziebuhr, LL. Poon, Y. Guan, M. Rozanov, WJ. Spaan, AE. Gorbalenya. (2003) Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol. 331(5): 991-1004. 14. MA. Marra, SJ. Jones, CR. Astell, RA. Holt, A. Brooks-Wilson, YS. Butterfield, J. Khattra, JK. Asano, SA. Barber, SY. Chan, A. Cloutier, SM. Coughlin, D. Freeman, N. Girn, OL. Griffith, SR. Leach, M. Mayo, H. McDonald, SB. Montgomery, PK. Pandoh, AS. Petrescu, AG. Robertson, JE. Schein, A. Siddiqui, DE. Smailus, JM. Stott, GS. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, TF. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, GA. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, RC. Brunham, M. Krajden, M. Petric, DM. Skowronski, C. Upton, RL. Roper. (2003) The genome sequence of the SARS-associated coronavirus. Science. 300(5624): 1399-1404. 15. J. Ziebuhr, EJ. Snijder, AE. Gorbalenya. (2000) Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol. 81: 853-879. 16. V. Thiel, KA. Ivanov, Á. Putics, T. Hertzig, B. Schelle, S. Bayer, B. Weißbrich, EJ. Snijder, H. Rabenau, HW. Doerr, AE. Gorbalenya, J. Ziebuhr. (2003) Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen Virol. 84: 2305-2315. 17. V. Thiel, J. Herold, B. Schelle, SG. Siddell. (2001) Viral replicase gene products suffice for coronavirus discontinuous transcription. J Virol. 75: 6676-6681. 18. TM. Gallagher. (2001) Murine coronavirus spike glycoprotein. Receptor binding and membrane fusion activities. Adv Exp Med Biol. 494: 183-192. 19. TM. Gallagher, MJ. Buchmeier. (2001) Coronavirus spike proteins in viral entry and pathogenesis. Virology. 279: 371-374. 20. KV. Holmes. (2003) SARS-associated coronavirus. N Engl J Med. 348(20): 1948-1951. 21. WH. Li, MJ. Moore, N. Vasilieva, JH. Sui, SK. Wong, MA. Berne, M. Somasundaran, JL. Sullivan, K. Luzuriaga, TC. Greenough, H. Choe , M. Farzan. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426: 450-454. 22. SK. Wong, WH. Li, MJ. Moore, H. Choe, M. Farzan. (2003) A 193-amino-acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol Chem. 279(5): 3197-3201. 23. J. Maeda, JF. Repass, A. Maeda, S. Makino. (2001) Membrane topology of coronavirus E protein. Virology. 15; 281(2): 163-169. 24. K. Narayanan, A. Maeda, J. Maeda, S. Makino. (2000) Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. J Virol. 74(17): 8127-8134. 25. JG. Breman, DA. Henderson. (2002) Diagnosis and management of smallpox. N Engl J Med. 346(17): 1300-1308. 26. L. Baillie. (2001) The development of new vaccines against Bacillus anthracis. J Appl Microbiol. 91(4): 609-613. 27. SA. Plotkin. (2000) Rabies. Clin Infect Dis. 30(1): 4-12. 28. JD. Cherry, U. Heininger. Pertussis and other Bordetella infections. In: RD. Feigin, JD. Cherry, eds. (1998) Textbook of Pediatric Infectious Diseases. 4th ed. Philadelphia, PA: WB Saunders Co; 2:1423-1439 29. F. Winau, R. Winau. (2002) Emil von Behring and serum therapy. Microbes Infect. 4(2): 185-188. 30. HL. Robinson. (1997) Nucleic acid vaccines: an overview. Vaccine. 15(8): 785- 787. 31. JJ. Donnelly, JB. Ulmer, JW. Shiver, MA. Liu. (1997) DNA Vaccines. Annu Rev Immunol. 15:617-648. 32. B. Wang, AP. Godillot, MP. Madaio, DB. Weiner, WV. Williams. (1998) Vaccination against pathogenic cells by DNA inoculation. Curr Top Microbiol Immunol. 226: 21-35. 33. DC. Tang, M. Devit, SA. Johnson. (1992) Genetic immunization is a simple method for eliciting an immune response. Nature. 356: 152-154. 34. L. Vanderzanden, M. Bray, D. Fuller, T. Roberts, D. Custer, K. Spik, P. Jahrling, J. Huggins, A. Schmaljohn , C. Schmaljohn. (1998) DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 246(1): 134-144. 35. DK. Singh, Z. Liu, D. Sheffer, GA. Mackay, M. Smith, S. Dhillon, R. Hegde, F. Jia, I. Adany, O. Narayan. (2005) A noninfectious simian/human immuno- deficiency virus DNA vaccine that protects macaques against AIDS. J Virol. 79(6): 3419-3428. 36. AP. Wlazlo, H. Deng, W. Giles-Davis, HC. Ertl. (2004) DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther. 11(6): 457-464. 37. D. Wang, ME. Christopher, LP. Nagata, MA. Zabielski, H. Li, JP. Wong, J. Samuel. (2004) Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J Clin Virol. Suppl 1: S99-106. 38. G. Romano, P. Micheli, C. Pacilio, A. Giordano. (2000) Latest developments in gene transfer technology : achievements, perspectives, and controversies over therapeutic applications. Stem Cells. 18(1): 19-39. 39. CD. Rocha, BC. Caetano, AV. Machado, O. Bruña-Romero. (2004) Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol. 7(2): 83-94. 40. JL. Brandsma, M. Shlyankevich, L. Zhang, MaD. Slade, EC. Goodwin, W. Peh, AB. Deisseroth. (2004) Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J Virol. 78(1): 116-123. 41. NL. Letvin, Y. Huang, BK. Chakrabarti, L. Xu, MS. Seaman, K. Beaudry, B. Korioth-Schmitz, F. Yu, D. Rohne, KL. Martin, A. Miura, WP. Kong, ZY. Yang, RS. Gelman, OG. Golubeva, DC. Montefiori, JR. Mascola, GJ. Nabel. (2004) Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol. 78: 7490-7497. 42. S. Jaiswal, N. Khanna, S. Swaminathan. (2003) Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol. 77(23): 12907-12913. 43. NJ. Sullivan, TW. Geisbert, JB. Geisbert, L. Xu, Z. Yang, M. Roederer, RA. Koup, PB. Jahrling, GJ. Nabel. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 7;424(6949): 681-684. 44. WS. Gallichan, KL. Rosenthal. (1998) Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis. 177(5): 1155-1161. 45. M. Matsui, O. Moriya, T. Akatsuka. (2003) Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine. 21(15): 1629-1639. 46. L. Wu, W. Kong, GJ. Nabel. (2005) Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol. 79(13): 8024-8031. 47. P. Zhao, JS. Ke, ZL. Qin, H. Ren, LJ. Zhao, JG. Yu, J. Gao, SY. Zhu, ZT. Qi. (2004) DNA vaccine of SARS-CoV S gene induces antibody respose in mice. Acta Biochim et Biophysica Sinica. 36(1): 37-41. 48. A. Bukreyev, EW. Lamirande, UJ. Buchholz, LN. Vogel, WR. Elkins, MS. Claire, BR. Murphy, K. Subbarao, PL. Collins. (2004) Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 363: 2122-2127. 49. S. Xiong, YF. Wang, MY. Zhang, XJ. Liu, CH. Zhang, SS. Liu, CW. Qian, JX. Li, JH. Lu, ZY. Wan, HY. Zheng, XG. Yan, MJ. Meng, JL. Fan. (2004) Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett. 95: 139-143. 50. H. Pang, Y. Liu, X. Han, Y. Xu, F. Jiang, D. Wu, X. Kong, M. Bartlam, Z. Rao. (2004) Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol. 85: 3109-3113. 51. Z. Chen, L. Zhang, C. Qin, L. Ba, CE. Yi, F. Zhang, Q. Wei, T. He, W. Yu, J. Yu, H. Gao, X. Tu, A. Gettie, M. Farzan, K. Yuen, DD. Ho. (2005) Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 79(5): 2678-2688. 52. W. Gao, A. Tamin, A. Soloff, L. D’Aiuto, E. Nwanegbo, PD Robbins, WJ. Bellini, S. Barratt-Boyes, A. Gambotto. (2003) Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 362: 1895-1896. 53. SH. Yeh, HY. Wang, CY. Tsai, CL. Kao, JY. Yang, HW. Liu, IJ. Su, SF. Tsai, DS. Chen, PJ. Chen, the National Taiwan University SARS Research Team. (2004) Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution. Proc Natl Acad Sci U S A. 101(8): 2542-2547. 54. H. Laude, J. Gelfi, L. Lavenant, B. Charley. (1992) Single amino acid changes in the viral glycoprotein M affect induction of alpha interferon by the coronavirus transmissible gastroenteritis virus. J. Virol. 66(2): 743-749. 55. IM. Antón, S. González, MJ. Bullido, M. Corsín, C. Risco, JP. Langeveld, L. Enjuanes. (1996) Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies. Virus Res. 46(1-2): 111-124. 56. A. Mandic, T. Vujkov. (2004) Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol. 15(2): 197-200. 57. L. Yuan, C. Iosef, MS. Azevedo, Y. Kim, Y. Qian, A. Geyer, TV. Nguyen, KO. Chang, LJ. Saif. (2001) Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs. J Virol. 75(19): 9229-9238. 58. SC. Gilbert, SJ Schneider, CM. Hannan, JT. Hu, M. Plebanski, R. Sinden, AV. Hill. (2002) Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 20(7-8): 1039-1045. 59. SH. Park, SH. Yang, CG Lee, JW Youn, J. Chang, YC. Sung. (2003) Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine. 21(31): 4555-4564. 60. ZY. Yang, LS Wyatt, WP. Kong, Z. Moodie, B. Moss, GJ Nabel. (2003) Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol. 77: 799-803. 61. Z. Wang, Z. Yuan, M. Matsumoto, UR. Hengge, YF. Chang. (2005) Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice. Biochem Biophys Res Commun. 327(1): 130-135. 62. MS. Zhu, Y. Pan, HQ. Chen, Y. Shen, XC. Wang, YJ. Sun, KH. Tao. (2004) Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol Lett. 92(3): 237-243. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35505 | - |
dc.description.abstract | 嚴重急性呼吸道症候群(severe acute respiratory syndrome,SARS)為一具有高度傳染性和高致死率的新興疾病,在2002年至2003年間造成全球性的流行。研究發現引起SARS的病原為一新種的冠狀病毒,稱作SARS-associated coronavirus (SARS-CoV)。臨床研究顯示,SARS病患可產生抗病毒結構蛋白的中和性抗體,加上目前並無有效對抗SARS的治療方法,因此發展預防性的SARS疫苗至為迫切。
重組腺病毒可攜帶並有效表現外來基因,是目前廣泛應用的疫苗系統。本論文的主要研究方向是以Balb/c小鼠的動物模式,測試帶有SARS病毒基因的DNA與重組腺病毒疫苗。重組腺病毒(Adv/SME)疫苗的設計是於腺病毒載體上攜帶三種SARS-CoV結構蛋白質基因:棘蛋白(spike protein,簡稱S)、膜蛋白(membrane protein,簡稱M)以及套膜蛋白(small envelope protein,簡稱E)基因。本研究的第一部份即是製備DNA與重組腺病毒兩種疫苗,並在293A細胞測試DNA疫苗之病毒基因表現。首先以大量製備的方式純化出質體DNA疫苗(pShuttle/SME),並進行質體DNA轉染,將pShuttle/SME送入293A細胞,利用反轉錄-聚合酶鏈鎖反應與西方墨點法,分別偵測三種病毒基因的mRNA與蛋白質表現。結果發現S、M、E基因在293A 細胞內皆有mRNA的表現,但無法以西方墨點法測得蛋白質的表現。另外,將Adv/SME以293A細胞大量複製並純化,取得高效價的重組腺病毒疫苗之後,對八週大的Balb/c小鼠進行疫苗施打,爲比較不同施打策略誘發之免疫反應,施打方式分為兩種:(一) 單次施打重組腺病毒疫苗,稱為one-shot接種;(二) 先施打三劑DNA疫苗,每劑相隔兩週,四週後再追加一劑重組腺病毒疫苗,稱為prime-boost接種。施打疫苗過程中於特定時間點採集小鼠血清,分析其抗體反應。 為偵測免疫小鼠的血清抗體,以評估疫苗所引發免疫反應之成效,論文第二部分乃利用大腸桿菌表現GST-E融合蛋白質(fusion protein),先分別以抗E蛋白之兔子抗血清與抗GST蛋白之小鼠單株抗體確定GST-E蛋白質於大腸桿菌中的表現量,之後利用其為抗原來源,以西方墨點法偵測免疫小鼠的抗體反應。觀察one-shot接種組的小鼠血清,發現免疫後並未測得專一性的抗體反應;而prime-boost接種組的免疫後血清,雖然出現抗體反應,但比較實驗組與對照組的結果,兩者並無顯著差異。 | zh_TW |
dc.description.abstract | The severe acute respiratory syndrome (SARS) is a newly emerged disease with high infectivity and morbidity, which caused massive outbreak worldwide from 2002 to 2003. The causative agent for SARS has been identified as a novel coronavirus named SARS-associated coronavirus (SARS-CoV). Clinical trials on SARS patients demonstrated that these people developed neutralizing antibodies against virus structural proteins. To date there is no efficient treatment for SARS, so the development of preventive vaccines is urgently necessary.
Recombinant adenovirus (ADV) is a widely used viral vector system and is known for effective delivery of foreign genes and high-level protein expression. In this study, we immunized Balb/c mice with DNA and recombinant adenovirus-based SARS vaccines. We used the recombinant ADV,Adv/SME,as vaccine which contains three of SARS-CoV structure protein genes, spike (S), membrane (M) and envelope (E). At the first part of this study,we prepared DNA and recombinant adenovirus vaccines, and evaluated the gene expression of DNA vaccine in 293A cells. First of all, the plasmid DNA vaccine,pShuttle/SME,was purified by massive preparation. Reverse transcription-polymerase chain reaction and western blotting were carried out to detect the expression of S, M and E genes in 293A cells transfected with pShuttle/SME. The mRNA expression of three genes was detectable; however, respective protein expression was non-detectable via western blot assay. On the other hand, high-titer Adv/SME was amplified in 293A cells. Two immunization strategies were performed in eight-weeks Balb/c mice to compare their efficiency in inducing antibody responses. The single shot immunization of recombinant adenovirus vaccine is so-called one-shot vaccination, while three DNA vaccines priming then one recombinant adenovirus boosting is so-called prime-boost vaccination. Collection of mouse sera was accompanied with the vaccination regimen. For preparing antigen sources to detect antibody responses of immunized mice,the GST-E fusion protein was expressed in E. coli and was confirmed by western blotting. The GST-E fusion protein could be detected by rabbit anti-E antisera and mouse anti-GST monoclonal antibody. Then we measured the antibody responses of immunized mice via western blotting using GST-E fusion protein. It was shown that no specific anti-E antibody was detected after one-shot vaccination. Similarly, there was no significant differences between experimental and control sets after prime-boost vaccination, either. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:55:52Z (GMT). No. of bitstreams: 1 ntu-94-R92424007-1.pdf: 5377730 bytes, checksum: d5a19803dcb13450eb2d12e51afc4679 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 目錄 Ⅰ
圖目錄 Ⅲ 表目錄 Ⅳ 中文摘要 Ⅴ 英文摘要 Ⅶ 第一章 緒論 1 第一節、SARS簡介 1 壹、緣起 1 貳、臨床症狀 1 參、治療 1 第二節、SARS冠狀病毒 1 壹、病毒分類 1 貳、基本結構 2 第三節、疫苗的歷史 4 壹、疫苗的緣起 4 貳、疫苗的原理 4 第四節、腺病毒疫苗 6 壹、腺病毒 (Adenovirus) 6 貳、重組腺病毒 (recombinant adenovirus) 6 參、重組腺病毒的優點 6 肆、重組腺病毒疫苗的臨床應用 7 第五節、SARS疫苗的研發 8 第六節、研究目的與實驗設計 8 第二章 材料與方法 10 第一節、實驗材料 10 第二節、實驗方法 15 壹、小鼠之SARS疫苗接種 15 貳、DNA疫苗之SARS病毒基因表現 19 參、以大腸桿菌表現SARS病毒E及M基因 24 肆、疫苗接種之小鼠血清抗體檢測 27 第三章 結果 29 第一節、小鼠之SARS疫苗接種 29 壹、製備DNA與重組腺病毒疫苗 29 貳、小鼠免疫實驗 29 第二節、DNA疫苗之SARS病毒基因表現 30 壹、病毒基因mRNA表現 30 貳、病毒蛋白表現 30 第三節、以大腸桿菌表現SARS病毒基因 32 壹、GST-E融合蛋白 32 貳、GST-M融合蛋白 33 第四節、疫苗接種之小鼠血清抗體檢測 34 壹、西方墨點法 34 貳、免疫螢光染色法 35 第四章、討論 37 圖 41 表 60 附錄 63 參考資料 66 | |
dc.language.iso | zh-TW | |
dc.title | 以SARS-CoV之DNA及重組腺病毒疫苗免疫小鼠並利用大腸桿菌系統表現SARS-CoV套膜蛋白 | zh_TW |
dc.title | Immunization of mice with DNA- and recombinant adenovirus-based SARS-CoV vaccines and expression of SARS-CoV envelope protein via E. coli system | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李君男,高全良,胡忠怡,張淑媛 | |
dc.subject.keyword | 嚴重急性呼吸道症候群,冠狀病毒,重組腺病毒疫苗, | zh_TW |
dc.subject.keyword | SARS-CoV,coronavirus,recombinant adenovirus vaccine, | en |
dc.relation.page | 70 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2005-07-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫事技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 5.25 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。